By Diagnostics World News Staff
July 9, 2024 | Proscia and Nucleai are partnering to integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s AI-enabled pathology portfolio to better inform patient care.
Nucleai’s predictive biomarkers create an AI-guided spatial map of a patient biopsy that will support clinical trial optimization, helping target recruitment. The same spatial mapping will also enable Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment.
“Today’s advanced therapies require advanced diagnostics,” said David West, Proscia’s CEO, in a press release. “Software-based approaches, made possible by the proliferation of pathology imaging and AI capabilities, offer a radical new option for bringing these treatments to patients. By expanding our AI pipeline with Nucleai’s solutions, we will elevate the role of the diagnostic laboratory in precision medicine to benefit drug developers, pathologists, and patients alike.”
Proscia’s Concentriq is an enterprise pathology platform for all digital pathology data. With a growing portfolio of applications from Proscia, Proscia’s customers, and leading third parties, it is addressing the widest range of AI use cases on a single platform. Nucleai's predictive biomarker solutions have a broad reach, being used by over 60% of the top 20 biopharma companies.
“Together, Proscia and Nucleai will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions,” said Avi Veidman, Nucleai’s CEO, in the same statement. “Our partnership holds tremendous promise for advancing next-generation treatment modalities like ADCs, multispecifics, immunotherapy, and combination therapies. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale. Together with Proscia, we can fundamentally improve the efficiency and effectiveness of introducing groundbreaking treatments and advancing patient care.”
The companies hope that the partnership will advance treatment modalities like ADCs, multispecifics, immunotherapy, and combination therapies, improving trial and diagnostic efficiency.